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Situ Xue et al.3141. Introduction
Viruses are the most common cause of global infectious disease.
Viruses with high infection rates and rapid propagation can cause
worldwide human and animal pandemics.
Coxsackie B viruses are single-strand RNA viruses; infection
with Cox B can cause fever, headache, chest pain and other
problems. Cardiac infection with Cox B3 can result in acute
myocarditis that is spontaneously resolved or chronic myocar-
ditis with prolonged viral persistence1. Currently, there is no
speciﬁc treatment or vaccine available for Coxsackie virus
infections.
Inﬂuenza is a respiratory disease caused by the inﬂuenza virus.
Despite the extensive effort invested in attempting to control
inﬂuenza infection, only two classes of drugs are currently
clinically available: inhibitors of the M2 protein (e.g., amanta-
dine and rimantadine), and inhibitors of neuraminidase (e.g.,
zanamivir and oseltamivir). Clinical applications of amantadine
and rimantadine have been limited as a consequence of the
increasing incidence of adamantane-resistant viruses in the
general population2–4. Furthermore, blockers of the M2 ion
channel inhibit only the replication of inﬂuenza A virus and
are associated with neurological side effects. The neuraminidase
inhibitors (zanamivir and oseltamivir) were marketed in 1999 for
the treatment and prophylaxis of inﬂuenza and have been
subsequently stockpiled by many countries for use in the event
of a pandemic. Unfortunately, recent studies have identiﬁed
signiﬁcant increases in the frequency of oseltamivir-resistant
seasonal inﬂuenza A (H1N1) in Europe, the United States,
Oceania and South Africa5–7.
Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are
human herpes viruses belonging to family Herpesviridae8. These
types of HSV are responsible for mucocutaneous infections,
mainly in immunocompromised patients. HSV-1 provokes orofa-
cial lesions, while HSV-2 causes mucocutaneous genital infec-
tions9. Antiviral research on HSV preliminarily focuses on
compounds capable of targeting the viral polymerase. Acyclovir,
a nucleoside inhibitor of DNA polymerase, was the ﬁrst selective
antiviral agent introduced. Acyclovir is still commonly employed
in the treatment of HSV infection10, but the widespread use of this
drug has led to the development of viral resistance. Therefore, the
search for new drugs against acyclovir-resistant HSV viruses is
highly necessary.
Most current antiviral drugs, including those in development,
are direct-acting antiviral (DAA) molecules that speciﬁcally target
viral proteins. These drugs are narrow in spectrum and are
vulnerable to the rapid emergence of viral resistance11. The
emergence of drug-resistant viruses, especially multidrug-
resistant strains, represents a signiﬁcant problem in current clinical
practice that needs to be addressed and should be considered a
high priority for new avenues of research12,13. To fulﬁll all of these
requirements, novel classes of antivirals are needed14. Addition-
ally, due to the high mutation rates that are particularly prevalent
in RNA viruses, the lifetime of speciﬁc antiviral therapeutics is
often severely limited. Broad spectrum antivirals would be one
way of circumventing this problem15. Therefore, a crucial need for
developing of new agents with novel antiviral mechanisms and
broad antiviral activities exists.
Our group has long been engaging antivirus drug research16–18.
Previously, we have done high-throughput screening of self-
owned compounds for drugs with anti-inﬂuenza activity, and have
found a group of indole-2-carboxylate derivatives with potentialanti-inﬂuenza activity. Analysis proved broad-spectrum antiviral
activity of these compounds and suggested the need for further
work with these agents. In the current work, a series of indole-2-
carboxylate derivatives were synthesized and evaluated for their
broad spectrum antiviral activity. Four virus strains, including
herpes viruses (HSV-1), Inﬂuenza viruses (A/FM/1/47, B/Jifang/
13/97) and picorna viruses (Cox B3) were selected to investigate
in vitro antiviral activities of the synthesized indole-2-carboxylate
derivatives. Antiviral activity experiments in vitro of hepatitis
viruses (HBV and HCV) and retrovirus (HIV-1) are not yet
complete.2. Results and discussion
2.1. Chemistry
The structure modiﬁcation in this work was primarily made to the
4, 6 and 7-position of the indole ring. Compounds 1f–10f with
substituents at the 4 and 6-position of the indole ring were
synthesized and screened for the antiviral activity. Compounds
12e with alkoxyl substituents at the 6-position of indole ring were
synthesized and screened for the antiviral activity. Additionally,
compounds 11e, 13e, 14f, 15e without amino or alkoxyl group at
the 4-position or the 6-position of indole scaffold were designed to
probe the importance of alkoxyl group and amino group for the
antiviral activity, respectively. Compounds 16f–18f with alkoxyl
and amino substituents at both 4 and 7-position were designed to
gain an insight into the SAR at those positions.
As shown in Scheme 1, compounds 2f–8f were synthesized
according to a reported method with some modiﬁcations19. Methyl
p-acetaminosalicylate was used as the starting material to react
with a variety of alkyl halide affording compounds 2a–8a. When
substituted benzyl bromide or allyl bromide was used (2b–4b, 6b),
a mild base (anhydrous K2CO3) was potent enough to drive the
reaction to completion. However, in the case of saturated alkyl
iodide (5b, 7b, 8b), a strong base (NaH) was employed for a
reasonable yield. Reduction of compounds 2a–8a by lithium
aluminum hydride (LiAlH4) in tetrahydrofuran (THF) yielded
corresponding alcohol derivatives 2b–8b, which were further
oxidized to afford compounds in the presence of a mild oxidation
reagent (BaMnO4). However, the use of BaMnO4 required a
prolonged reaction time (24 h) and resulted in moderate yields.
The use of an alternative oxidant pyridinium dichromate (PDC)20
reduced the reaction time to 2 h, and compounds 2c–8c were
obtained in high yields (85%–90%). During the aldehyde (2c–8c)
condensing steps with methyl azidoacetate, the intermediate
compounds with high polarity (i.e., small Rf values of TLC)
was observed, which were subsequently transformed into com-
pounds 2d–8d. Compounds 2d–8d were not characterized in this
work due to their instability. Thermolysis of compounds 2d–8d in
boiling xylene afforded the expected indole compounds 2e–8e in
60%–70% yield over two steps. The acid cleavage of acetamide in
a boiling hydrogen chloride solution of methanol produced
compounds 2f–8f.
As shown in Scheme 2, compounds 1e, 9e–18e with various
alkoxyl substituents at 4, 6 and 7 position of the indole scaffold
were obtained using a method similar to that employed to
synthesize compounds 2e–8e, and compounds 1e, 9e, 10e, 14e,
16e–18e were further deacetylated to afford compound 1f, 9f, 10f,
14f, 16f–18f.
Scheme 2 Synthetic route of the target compounds 1f, 9f–10f, 14f, 16f–18f. Reagents and conditions: (a) N3CH2COOEt, MeONa/MeOH,
15 1C, 1 h, then, 0 1C, 20 h; (b): xylene, reﬂux, 2 h, 85%; (c) HCl(g)/MeOH, reﬂux, 3 h, 78%.
Scheme 1 Synthetic route of the target compounds 2f–8f. Reagents and conditions: (a) K2CO3, acetone, R3X (X¼Br, I), reﬂux, 4–8 h, or NaH,
DMF, R3X, 80 1C, 8 h; 70%-90%; (b) LiAlH4, dry THF, –5 1C, 2 h, 80%–90%; (c) PDC, CH2Cl2, reﬂux, 3 h, 90%; (d) N3CH2COOEt, MeONa/
MeOH, 15 1C, 1 h, then, 0 1C, 20 h; (e) xylene, reﬂux, 2 h, 85%; (f) HCl (g)/MeOH, reﬂux, 3 h, 78%;
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The synthesized compounds were assayed for their broad spectrum
antiviral activity towards inﬂuenza A, inﬂuenza B, HSV-1 and
Cox B3 virus in vitro. Speciﬁcally, the activity against inﬂuenza A
and Cox B3 was determined by the cytopathic effect (CPE)
inhibitory assay, and oseltamivir and ribavirin (RBV) were used as
positive controls, respectively. A total of 22 compounds were
evaluated, and the results are summarized in Table 1.2.2.1. Anti Cox B3 virus activity
As shown in Table 1, 50% of the synthesized compounds showed
potent inhibitory activity towards Cox B3 at low micromolar concen-
trations, especially compounds 2f (IC50¼1.59 μmol/L), 3f (IC50¼4.55
μmol/L), 8f (IC50¼7.18 μmol/L) and 17f (IC50¼10.56 μmol/L). TheIC50 value of RBV (the positive control) was 1058.68 μmol/L. Of all
the compounds tested, compound 8f showed the highest SI value
(17.1). Compounds 15e, 6f and 18f exhibited moderate levels of
inhibitory activity against the Cox B3 virus, with IC50 values less then
50 μmol/L.
Given that compounds 14e, 14f and 15e showed anti-Cox B3
activity, we concluded that the 4-alkyloxy substituent of the indole
ring was not crucial to antiviral activity. Relocation of the 6-amino
substituent to the 7-position retained activity. Acetyl substituent at
the amino group (1e and 2e) disfavored the antiviral activities.2.2.2. Anti HSV-1 virus activity
HSV-1 was less sensitive to the presently-synthesized compounds
compared to inﬂuenza A and Cox B3 virus. Only compounds 15e
and 17f showed activity towards HSV-1.
Table 1 The antiviral activity and cytotoxicity of the compounds.
Compd. Cox B3 HSV-1 A/FM/1/47 B/Jifang/13/97
TC50 (μmol/L) 158TCID50 TC50 (μmol/L) 100TCID50 TC50 (μmol/L) 158TCID50 TC50 (μmol/L) 100TCID50
IC50 (μmol/L) SI IC50 (μmol/L) SI IC50 (μmol/L) SI IC50 (μmol/L) SI
1e 763.36 4254.47 – 763.36 4254.47 – 763.36 254.47 3.0 763.36 254.47 3.0
2e 45.59 421.92 – 45.59 421.92 – 341.63 465.73 – NT NT NT
8e 50.69 424.38 – 50.69 424.38 – 24.38 8.13 3.0 24.38 48.13 –
11e 225.46 108.39 2.1 225.46 4108.39 – 225.46 62.59 3.6 225.46 4108.39 –
12e 49.55 47.94 – 49.55 47.94 – 92.06 23.83 3.9 92.06 423.83 –
13e 54.84 48.79 – 54.84 48.79 – 136.98 26.37 5.2 136.98 426.37 –
14e 597.71 72.80 8.2 597.71 4287.37 – 414.44 95.78 4.3 414.44 495.78 –
15e 212.02 44.72 4.7 212.02 101.93 2.1 711.97 101.93 7.0 711.97 4101.93 –
1f 174.95 433.68 – 174.95 433.68 – 174.95 33.68 5.2 174.95 433.68 –
2f 14.51 1.59 9.1 14.51 42.78 – 108.64 425.12 – NT NT NT
3f 16.37 4.55 3.6 16.37 47.87 – 273.57 470.76 – NT NT NT
4f 52.91 47.58 – 52.91 47.58 – 354.20 4204.51 – NT NT NT
5f 11.75 42.71 – 11.75 48.15 – 14.13 48.15 – NT NT NT
6f 210.33 30.12 7.0 210.33 430.12 – 130.28 30.12 4.3 130.28 430.12 –
7f 177.77 49.35 3.6 177.77 485.46 – 177.77 485.46 - NT NT NT
8f 122.33 7.18 17.1 122.33 428.28 – 40.76 9.43 4.3 40.76 49.43 –
9f 94.96 431.67 – 94.96 431.67 – 65.85 18.29 3.6 65.85 431.67 –
10f 625.85 489.60 – 625.85 489.60 – 465.60 51.73 9.0 465.60 489.60 –
14f 243.26 67.53 3.6 243.26 4116.95 – 90.79 7.53 12.1 90.79 13.00 7.0
16f 145.68 433.68 – 145.68 433.68 – 11.23 43.73 – NT NT NT
17f 18.29 10.56 1.7 31.67 10.56 3.0 31.67 410.56 – NT NT NT
18f 115.44 29.88 3.9 115.44 429.88 - 5.77 43.31 – NT NT NT
RBV 8190.01 1058.68 7.7 NT NT NT 4766.99 2.58 1847.8 4766.99 10.11 471.3
ACV NT NT NT 4444.05 1.82 4243.9 NT NT NT NT NT NT
Oseltamivir NT NT NT NT NT NT 4033.29 6.43 626.9 4033.29 115.04 35.1
TC50, 50% cytotoxic concentration; IC50, 50% inhibition concentration; SI, the selectivity index. NT means not tested.
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As shown in Table 1, the majority of the synthesized compounds
exhibited potent antiviral activity towards inﬂuenza A/FM/1/47
virus. This was particularly true for compounds 8e (IC50¼8.13
μmol/L), 8f (IC50¼9.43 μmol/L) and 14f (IC50¼7.53 μmol/L).
These IC50 values were comparable to those of the positive control
drugs RBV (IC50¼2.58 μmol/L) and oseltamivir (IC50¼6.43
μmol/L). Of all the compounds tested, compound 14f showed
both potent inhibitory activity against inﬂuenza A (IC50¼7.53
μmol/L) and the highest SI value (12.1). Compounds 12e, 13e, 1f,
6f and 10f exhibited moderate levels of inhibitory activity against
the A/FM/1/47 strain of the inﬂuenza virus, with IC50 values less
then 52 μmol/L.
The compounds exhibiting activity against the A/FM/1/47
(H1N1) strain of the inﬂuenza virus were further evaluated for
their potential antiviral activity against strain of the inﬂuenza B
virus, also using the CPE method. Compounds 1e and 14f also
displayed antiviral activity against the inﬂuenza B strain. Com-
pound 14f (IC50¼13.00 μmol/L) was found to be the most
effective compound against the B/Jingfang/13/97 strain of the
inﬂuenza virus, with an IC50 value comparable to that of the
positive control RBV (IC50¼10.11 μmol/L).
In terms of the structure-activity relationships, substitution
of the benzyloxy (2f–4f) for the alkyloxy (8f–10f) at the 4-
position of the indole ring decreased the anti-inﬂuenza A
activity. Replacement of the amino group at the 6-position of
the indole ring (1f, 9f) with hydrogen (11e, 16f and 17f)
resulted in a dramatic decrease in the anti-inﬂuenza A activity.
Thus, the 6-amino group in the indole ring is indispensable to
the antiviral activities. Additionally, introduction of the acetyl
substituent at the amino group (1e and 2e) disfavored the anti-
inﬂuenza A activity. Given that compounds 14e, 14f and 15e
showed anti-inﬂuenza A activity, we concluded that the
alkyloxy at the 4-position of indole ring was not crucial to
the anti-inﬂuenza A activities. In addition, as the activity of
compound 8f was superior to that of 10f, it can be concluded
that a more bulky alkyloxy substituent at the 4-position of
indole ring favored the anti-inﬂuenza A activity.3. Conclusions
In summary, a total of 22 indole-2-carboxylate derivatives
were designed, synthesized and screened for antiviral activities
towards inﬂuenza A, inﬂuenza B, HSV-1 and Cox B3. In
general, the target compounds were more effective against
RNA viruses (inﬂuenza A and Cox B3) than against the DNA
virus (HSV-1). The majority of the synthesized compounds
simultaneously exhibited potent activity against the inﬂuenza
A and Cox B3 viruses. A similar trend was observed among
the SARs of the synthesized compounds towards the RNA
virus. For example, the alkyloxy at the 4-position of indole
ring was not crucial to the antiviral activities. Acetyl sub-
stituent at the amino group also disfavored the antiviral
activities. Notably, compounds 8f and 14f showed potent
antiviral activity towards the RNA virus at low micromolar
concentrations. Compound 8f showed the highest SI value
(17.1) to Cox B3 virus. Compound 14f showed both potent
inhibitory activity against inﬂuenza A (IC50¼7.53 μmol/L)
and the highest SI value (12.1). The detailed structure
optimization of compound 8f and 14f and mechanistic studies
are ongoing in our laboratory.4. Experimental
4.1. Synthesis and characterization
1H NMR and 13C NMR spectra were recorded using TMS as the
internal standard in DMSO-d6 or CDCl3 with a Bruker BioSpin
GmbH spectrometer. The mass spectra (MS) were recorded on a
Thermo Scientiﬁc LTQ ORBITRAP instrument with an ESI mass
selective detector. Melting points (m.p.) were determined using an
SRS-OptiMelt automated melting point instrument, without cor-
rection. Flash column chromatography was performed with silica
gel (200–300 mesh) purchased from Qingdao Haiyang Chemical
Co., Ltd.4.1.1. General procedure A for the preparation of 2a–8a
Methyl 4-acetamido-2-hydroxybenzoate (20 mmol) was dissolved
in anhydrous DMF (50 mL), followed by the addition of anhy-
drous K2CO3 (30 mmol) or NaH (30 mmol) and alkylation agents
(30 mmol). The mixture was heated to 60 1C for 4–6 h, and the
reaction mixture was cooled to room temperature and ﬁltered. The
ﬁltrate was concentrated in vacuum, and the resulting residue was
recrystallized from ethyl acetate and petroleum ether to afford the
target compounds.
Methyl 4-acetamido-2-(benzyloxy)benzoate (2a): white solid,
yield, 90%; m.p. 107–108 1C. 1H NMR (400 MHz, CDCl3): δ 2.18
(s, 3H), 3.88 (s, 3 H), 5.18 (s, 2 H), 6.82 (d, 1H, J¼8.4 Hz), 7.30
(t, 1H, J¼7.6 Hz), 7.38 (t, 2H, J¼7.6 Hz), 7.51 (d, 2H, J¼7.6
Hz), 7.69 (s, 1H), 7.83 (d, 1H, J¼8.4 Hz).
Methyl 4-acetamido-2-(4-ﬂuorobenzyloxy)benzoate (3a): white
solid, yield, 85%; m.p. 132–133 1C. 1H NMR (400 MHz, CDCl3):
δ 2.20 (s, 3H), 3.88 (s, 3H), 5.15 (s, 2H), 6.76 (dd, 1H, J¼8.4,
1.6 Hz), 7.06 (m, 2H), 7.50 (m, 2H), 7.76 (s, 1H), 7.83 (d, 1H,
J¼8.4 Hz)
Methyl 4-acetamido-2-(4-methoxybenzyloxy)benzoate (4a):
white solid, yield, 90%. m.p. 124–125 1C. 1H NMR (400 MHz,
DMSO-d6): δ 2.05 (s, 3H), 3.73 (s, 3H), 3.74 (s, 3H), 5.03 (s, 2H),
6.94 (d, 2H, J¼8.4 Hz), 7.16 (d, 1H, J¼8.4 Hz), 7.40 (d, 2H,
J¼8.4 Hz), 7.56 (s, 1H), 7.66 (d, 1H, J¼8.4 Hz), 10.19 (s, 1H).
Methyl 4-acetamido-2-(cyclohexylmethoxy)benzoate (5a): white
solid, yield, 65%; m.p. 132–133 1C. 1H NMR (400 MHz, CDCl3): δ
1.05–1.32 (m, 5H), 1.68–1.90 (m, 6H), 2.23 (s, 3H), 3.83 (d, 2H,
J¼6.0 Hz), 3.87 (s, 3H), 6.79 (d, 1H, J¼8.4 Hz), 7.29 (s, 1H), 7.53
(s, 1H), 7.80 (d, 1H, J¼8.4 Hz).
Methyl 4-acetamido-2-(allyloxy)benzoate (6a): white solid,
yield, 90%; m.p. 114–115 1C. 1H NMR (400 MHz, DMSO-d6):
δ 2.06 (s, 3H), 3.74 (s, 3H), 4.54 (d, 2H, J¼6.4 Hz), 5.25 (d, 1H,
J¼6.4 Hz), 5.51 (d, 1H, J¼16.0 Hz), 6.02 (m, 1H), 7.16 (dd, 1H,
J¼8.4, 1.6 Hz), 7.47 (d, 1H, J¼1.6 Hz), 7.66 (d, 1H, J¼8.4 Hz),
10.18 (s, 1H).
Methyl 4-acetamido-2-(cyclopropylmethoxy)benzoate (7a):
white solid, yield 78%; m.p. 127–128 1C. 1H NMR (400 MHz,
CDCl3): δ 0.38 (t, 2H, J¼4.8 Hz), 0.59–0.64 (m, 2H), 1.30 (t, 1H,
J¼6.0 Hz), 2.19 (s, 3H), 3.87 (s, 3H), 3.92 (d, 2H, J¼6.4 Hz),
6.79 (d, 1H, J¼8.4 Hz), 7.33 (s, 1H), 7.59 (s, 1H), 7.78 (d, 1H,
J¼8.4 Hz).
Methyl 4-acetamido-2-isobutoxybenzoate (8a): white solid,
yield, 70%; m.p. 112–113 1C. 1H NMR (400 MHz, DMSO-d6):
δ 1.00 (d, 6H, J¼6.8 Hz), 2.01 (s, 3H), 2.03–2.05 (m, 1H), 3.72
(d, 2H, J¼7.2 Hz), 3.74 (s, 3H), 7.15 (dd, 1H, J¼8.4, 2.0 Hz),
7.44 (d, 1H, J¼2.0 Hz), 7.64 (d, 1H, J¼8.4 Hz), 10.16 (s, 1H).
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2b–8b
A suspension of LiAlH4 (25 mmol) in anhydrous THF (100 mL)
was added dropwise a solution of compounds 2a–8a (20 mmol) in
anhydrous THF (50 mL), maintaining the reaction temperature
blow 0 1C. After completion of the addition, the reaction mixture
was warmed up to room temperature for another 2 h, and was
cooled again with ice bath. Na2SO4  7H2O was added to quench
the reaction, and the resulting mixture was stirred for another 2 h
at room temperature. After that, the mixture was ﬁltered, and the
ﬁltrate was concentrated in vacuum to give a white solid, which
was triturated with ether to afford the target compounds.
N-(3-(Benzyloxy)-4-(hydroxymethyl)phenyl)acetamide (2b):
white solid, yield, 85%; m.p. 115–116 1C; 1H NMR (400 MHz,
DMSO-d6): δ 2.02 (s, 3 H), 4.48 (d, 2H, J¼5.6 Hz), 4.89 (t, 1H,
J¼5.6 Hz), 5.05 (s, 2 H), 7.12 (dd, 1H, J¼1.6, 8.0 Hz), 7.26 (d,
1H, J¼8.0 Hz), 7.32–7.46 (m, 6H), 9.87 (s, 1H).
N-(3-(4-Fluorobenzyloxy)-4-(hydroxymethyl)phenyl)acetamide
(3b): white solid, yield, 80%; m.p. 124–125 1C. 1H NMR
(400 MHz, DMSO-d6): δ 2.01 (s, 3H), 4.46 (d, 2 H, J¼5.6 Hz),
4.87 (t, 1H, J¼5.6 Hz), 5.02 (s, 2 H), 7.09 (d, 1H, J¼7.6 Hz),
7.22 (m, 3H), 7.37 (s, 1H), 7.49 (dd, 2H, J¼8.0, 5.6 Hz), 9.86
(s, 1H).
N-(4-(Hydroxymethyl)-3-(4-methoxybenzyloxy)phenyl)aceta-
mide (4b): white solid, yield, 85%. m.p. 140–142 1C. 1H NMR
(400 MHz, DMSO-d6): δ 2.01 (s, 3H), 3.75 (s, 3H), 4.43 (d, 2H,
J¼5.6 Hz), 4.85 (t, 1H, J¼5.6 Hz), 4.95 (s, 2 H), 6.93 (d, 2H,
J¼8.4 Hz), 7.08 (d, 1H, J¼8.4 Hz), 7.23 (d, 1H, J¼8.4 Hz), 7.36
(d, 3H, J¼8.4 Hz), 9.85 (s, 1H).
N-(3-(Cyclohexylmethoxy)-4-(hydroxymethyl)phenyl)aceta-
mide (5b): white solid, yield, 79%; m.p. 112–114 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.03–1.29 (m, 5H), 1.68–1.80 (m, 6H),
2.00 (s, 3H), 3.68 (d, 2H, J¼6.0 Hz), 4.42 (d, 2H, J¼5.2 Hz),
4.83 (t, 1H, J¼5.2 Hz), 7.07 (dd, 1H, J¼ 8.4, 1.6 Hz), 7.21 (d,
1H, J¼8.4 Hz), 7.24 (d, 1H, J¼1.6 Hz), 9.82 (s, 1H).
N-(3-(Allyloxy)-4-(hydroxymethyl)phenyl)acetamide (6b):
white solid, yield, 75%; m.p. 129–131 1C. 1H NMR (400 MHz,
DMSO-d6): δ 2.01 (s, 3H), 4.44 (d, 2H, J¼6.4 Hz), 4.49 (d, 2H,
J¼5.6 Hz), 4.86 (t, 1H, J¼5.6 Hz), 5.25 (d, 1H, J¼6.4 Hz), 5.40
(d, 1H, J¼17.2 Hz), 6.01–6.07 (m, 1H), 7.08 (dd, 1H, J¼8.4,
2.0 Hz), 7.23 (d, 1H, J¼8.4 Hz), 7.28 (d, 1H, J¼1.6 Hz), 9.85
(s, 1H).
N-(3-(Cyclopropylmethoxy)-4-(hydroxymethyl)phenyl)aceta-
mide (7b): white solid, yield, 79%. m.p. 120–121 1C. 1H NMR
(400 MHz, DMSO-d6): δ 0.30–0.34 (m, 2H), 0.52-0.57 (m, 2H),
1.19-1.22 (m, 1H), 2.20 (s, 3H), 3.76 (d, 2H, J¼6.8 Hz), 4.43 (d,
2H, J¼5.6 Hz), 4.83 (t, 1H, J¼5.6 Hz), 7.06 (dd, 1H, J¼8.4,
1.6 Hz), 7.22 (d, 1H, J¼8.4 Hz), 7.25 (d, 1H, J¼1.6 Hz), 9.82
(s, 1H).
N-(4-(Hydroxymethyl)-3-isobutoxyphenyl)acetamide (8b):
white solid, yield, 85%; m.p. 120–121 1C. 1H NMR (400 MHz,
DMSO-d6): δ 0.97 (d, 6H, J¼6.8 Hz), 2.00 (s, 3H), 2.02-2.03 (m,
1H), 3.65 (d, 2H, J¼6.4 Hz), 4.44 (d, 2H, J¼5.6 Hz), 4.84 (t, 1H,
J¼5.6 Hz), 7.06 (dd, 1H, J¼8.4, 2.0 Hz), 7.22 (d, 1H, J¼8.4
Hz), 7.26 (d, 1H, J¼2.0 Hz), 9.83 (s, 1H).4.1.3. General procedure C for the preparation of compounds
2c–8c
Compounds 2b-8b (20 mmol) was dissolved in CH2Cl2 (100 mL),
and PDC (30 mmol) was added. The resulting mixture was heated
under reﬂux for 2 h. The reaction mixture was cooled and ﬁlteredthrough a thin layer of silica gel, and the ﬁltrate was concentrated
in vacuum. The residue was recrystallized from ethyl acetate and
petroleum ether to afford the target compounds as white solid.
N-(3-(Benzyloxy)-4-formylphenyl)acetamide (2c): white solid,
yield, 90%; m.p. 126-128 1C. 1H NMR (400 MHz, DMSO-d6): δ
2.06 (s, 3H), 5.21 (s, 2H), 7.21 (d, 1H, J¼8.4 Hz), 7.35 (t, 1H,
J¼7.6 Hz), 7.42 (t, 2H, J¼7.6 Hz), 7.51 (d, 2H, J¼7.6 Hz), 7.65
(s, 1H), 7.68 (d, 1H, J¼8.4 Hz), 10.25 (s, 1H), 10.34 (s,1H).
N-(3-(4-Fluorobenzyloxy)-4-formylphenyl)acetamide (3c):
white solid, yield, 87%; m.p. 158-160 1C. 1H NMR (400 MHz,
CDCl3): δ 2.22 (s, 3H), 5.16 (s, 2H), 6.69 (d, 1H, J¼8.0 Hz), 7.08
(m, 2H), 7.35 (s, 1H), 7.43 (dd, 2H, J¼8.4, 5.6 Hz), 7.79 (d, 1H,
J¼8.0 Hz), 7.93 (s, 1H), 10.34 (s, 1H).
N-(4-Formyl-3-(4-methoxybenzyloxy)phenyl)acetamide (4c):
white solid, yield, 86%. m.p. 158-160 1C. 1H NMR (400 MHz,
DMSO-d6): δ 2.08 (s, 3H), 3.74 (s, 3H), 5.11 (s, 2H), 6.94 (d, 2H,
J¼8.4 Hz), 7.18 (d, 1H, J¼8.4 Hz), 7.42 (d, 2H, J¼8.4 Hz), 7.63
(d, 1H, J¼8.4 Hz), 7.69 (s, 1H), 10.20 (s, 1H), 10.33 (s, 1H).
N-(3-(Cyclohexylmethoxy)-4-formylphenyl)acetamide (5c):
white solid, yield, 90%, m.p. 156-157 1C. 1H NMR (400 MHz,
DMSO-d6): δ 1.06-1.27 (m, 5H), 1.70-1.83 (m, 6H), 2.07 (s, 3H),
3.85 (d, 2H, J¼6.0 Hz), 7.17 (d, 1H, J¼8.4 Hz), 7.53 (s, 1H),
7.62 (d, 1H, J¼8.4 Hz), 10.22 (s, 1H), 10.30 (s, 1H).
N-(3-(Allyloxy)-4-formylphenyl)acetamide (6c): white solid.
yield, 90%; m.p. 121-122 1C. 1H NMR (400 MHz, DMSO-d6): δ
2.08 (s, 3H), 4.65 (d, 2H, J¼6.8 Hz), 5.30 (d, 1H, J¼6.4 Hz),
5.48 (d, 1H, J¼16.0 Hz), 6.05-6.12 (m, 1H), 7.17 (dd, 1H, J¼8.4,
1.6 Hz), 7.58 (d, 1H, J¼1.6 Hz), 7.64 (d, 1H, J¼8.4 Hz), 10.24
(s, 1H), 10.32 (s, 1H).
N-(3-(Cyclopropylmethoxy)-4-formylphenyl)acetamide (7c):
white solid, yield, 82%. m.p. 152–153 1C. 1H NMR (400 MHz,
DMSO-d6): δ 0.37 (t, 2H, J¼4.8 Hz), 0.56-0.60 (m, 2H), 1.26-
1.29 (m, 1H), 2.07 (s, 3H), 3.92 (d, 2H, J¼6.8 Hz), 7.15 (d, 1H,
J¼8.4 Hz), 7.55 (s, 1H), 7.62 (d, 1H, J¼8.4 Hz), 10.24 (s, 1H),
10.30 (s, 1H).
N-(4-Formyl-3-isobutoxyphenyl)acetamide (8c): white solid,
yield, 84%, m.p. 133-134 1C. 1H NMR (400 MHz, DMSO-d6): δ
1.00 (d, 6H, J¼6.8 Hz), 2.07 (s, 3H), 2.10-2.11 (m, 1H), 3.82 (d,
2H, J¼6.4 Hz), 7.15 (d, 1H, J¼8.4 Hz), 7.56 (s, 1H), 7.63 (d, 1H,
J¼8.4 Hz), 10.24 (s, 1H), 10.31 (s, 1H).4.1.4. General procedure D for the preparation of compounds
1e–18e
To a solution of MeONa (30 mmol) in MeOH (80 mL) were added
aromatic aldehydes (20 mmol) and methyl 2-azidoacetate
(200 mmol) in anhydrous THF (80 mL) at –15 1C, and the mixture
was stirred for another 4 h. After that, the reaction was quenched
by the addition of saturated ammonium chloride solution, and
extracted with ethyl acetate (3 100 mL). The combined organic
layer was washed with brine, and dried over anhydrous MgSO4,
ﬁltered and concentrated, and the residue was triturated with
MeOH to give the intermediate compounds 1d–18d as yellow
solids. The crude compounds 1d–18d were dissolved in xylene,
and heated under reﬂux for 2 h. After cooling, white solids were
crystallized. Filtration afforded the target compounds.
Methyl 6-acetimidamido-4-methoxy-1H-indole-2-carboxylate
(1e): white solid, yield, 84%. m.p. 237–239 1C. 1H NMR
(400 MHz, DMSO-d6): δ 2.05 (s, 3H), 3.82 (s, 3H), 3.85
(s, 3H), 6.76 (s, 1H), 7.01 (s, 1H), 7.60 (s, 1H), 9.93 (s, 1H),
11.77 (s, 1H). HRMS (ESIþ): found 263.10238 (Calcd. for
C13H15O4N2 [MþH]þ: 263.10263).
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(2e): white solid, yield, 60%; m.p. 264-265 1C. 1H NMR
(400 MHz, DMSO-d6): δ 2.04 (s, 3H), 3.83 (s, 3H), 5.18
(s, 2H), 6.78 (s, 1H), 7.07 (s, 1H), 7.36 (t, 1H, J¼7.6 Hz), 7.42
(t, 2H, J ¼7.6 Hz), 7.51 (d, 2H, J¼7.6 Hz), 7.62 (s, 1H), 9.92
(s, 1H), 11.79 (s, 1H). 13C NMR (126 MHz, DMSO-d6): δ 24.62,
52.05, 69.50, 95.76, 105.79, 115.05, 125.86, 127.83, 128.27,
128.93, 137.45, 138.16, 139.37, 152.81, 161.90, 168.60. HRMS
(ESIþ): found 339.13379 (Calcd. for C19H19O4N2 [MþH]þ:
339.13393).
Methyl 6-acetamido-4-(4-ﬂuorobenzyloxy)-1H-indole-2-car-
boxylate (3e): white solid, yield, 60%; m.p. 273-273 1C. 1H
NMR (400 MHz, DMSO-d6): δ 2.03 (s, 3H), 3.82 (s, 3H), 5.15
(s, 2H), 6.78 (s, 1H), 7.05 (s, 1H), 7.23 (t, 2H, J¼8.4 Hz), 7.55
(dd, 2H, J¼ 5.6, 8.4 Hz), 7.60 (s, 1H), 9.92 (s, 1H), 11.79 (s, 1H).
HRMS (ESIþ): found 357.12429 (Calcd. for C19H18O4N2F
[MþH]þ: 357.12451).
Methyl 6-acetimidamido-4-(4-methoxyphenoxy)-1H-indole-2-
carboxylate (4e): pale yellow solid, yield, 80%. m.p. 268-
270 1C. 1H NMR (400 MHz, DMSO-d6): δ 2.03 (s, 3H), 3.76 (s,
3H), 3.81 (s, 3H), 5.08 (s, 2H), 6.77 (s, 1H), 6.95 (d, 1H,
J¼8.4 Hz), 7.01 (s, 1H), 7.42 (d, 1H, J¼8.4 Hz), 7.59 (s, 1H),
9.91 (s, 1H), 11.77 (s, 1H). HRMS (ESIþ): found 391.12626
(Calcd. for C20H20O5N2Na [MþNa]þ: 391.12644).
Methyl 6-acetamido-4-(cyclohexylmethoxy)-1H-indole-2-car-
boxylate (5e): pale yellow solid, yield, 63%; m.p. 253-255 1C.
1H NMR (400 MHz, DMSO-d6): δ 1.04-1.30 (m, 5H), 1.65-1.75
(m, 6H), 2.02 (s, 3H), 3.81 (s, 3H), 3.82 (d, 2H, J¼6.0 Hz), 6.63
(s, 1H), 7.01 (s, 1H), 7.57 (s, 1H), 9.87 (s, 1H), 11.74 (s, 1H).
HRMS (ESIþ): found 345.18094 (Calcd. for C19H25O4N2
[MþH]þ: 345.18088).
Methyl 6-acetamido-4-(allyloxy)-1H-indole-2-carboxylate (6e):
pale yellow solid, yield, 62%; m.p. 200-201 1C. 1H NMR
(400 MHz, DMSO-d6): δ 2.01 (s, 3H), 3.82 (s, 3H), 4.61 (d, 2H,
J¼5.2 Hz), 5.28 (d, 1H, J¼6.4 Hz), 5.45 (d, 1H, J¼17.2 Hz),
6.06-6.14 (m, 1H), 6.68 (s, 1H), 7.03 (s, 1H), 7.59 (s, 1H), 9.90 (s,
1H), 11.77 (s, 1H). HRMS (ESIþ): found 289.11805 (Calcd. for
C15H17O4N2 [MþH]þ: 289.11828).
Methyl 6-acetimidamido-4-cyclopropoxy-1H-indole-2-carboxy-
late (7e): Pale white solid, yield, 84%. m.p. 240-241 1C. 1H NMR
(400 MHz, DMSO-d6): δ 0.35-0.39 (m, 2H), 0.57-0.60 (m, 2H),
1.30-1.33 (m, 1H), 2.02 (s, 3H), 3.82 (s, 3H), 3.88 (d, 2H,
J¼6.8 Hz), 6.64 (s, 1H), 7.01 (s, 1H), 7.56 (s, 1H), 9.87 (s, 1H),
11.74 (s, 1H). HRMS (ESIþ): found 325.11577 (Calcd. for
C16H18O4N2Na [MþNa]þ: 325.11588).
Methyl 6-acetamido-4-isobutoxy-1H-indole-2-carboxylate (8e):
white solid, yield, 66%; m.p. 107–108 1C. 1H NMR (400 MHz,
DMSO-d6): δ 1.01 (d, 6H, J¼6.8 Hz), 2.03 (s, 3H), 2.06-2.11 (m,
1H), 3.78 (d, 2H, J¼6.4 Hz), 3.82 (s, 3H), 6.65 (s, 1H), 7.01 (s,
1H), 7.57 (s, 1H), 9.88 (s, 1H), 11.74 (s, 1H). 13C NMR
(150 MHz, DMSO-d6): δ 19.52, 24.62, 28.19, 52.02, 74.13,
95.33, 105.74, 114.99, 125.69, 138.26, 139.34, 153.31, 161.93,
168.58. HRMS (ESIþ): found 305.14938 (Calcd. for C16H21O4N2
[MþH]þ: 305.14958).
Methyl 6-acetimidamido-4-ethoxy-1H-indole-2-carboxylate
(9e): white solid, yield, 76%. m.p. 205-207 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.33 (s, 3H), 2.02 (s, 3H), 3.87 (s,
3H), 3.95 (s, 2H), 6.78 (s, 1H), 7.06 (s, 1H), 7.65 (s, 1H), 9.63 (s,
1H), 11.70 (s, 1H). HRMS ( ESIþ ): found 277.11863, (Calcd. for
C14H17O4N2 [MþH]þ: 277.11828).
Methyl 6-acetimidamido-4-isopropoxy-1H-indole-2-carboxylate
(10e): pale white solid, yield, 72%. m.p. 196-197 1C. 1H NMR(400 MHz, DMSO-d6): δ 1.38 (s, 6H), 2.03 (s, 3H), 3.88 (s, 3H),
4.04 (s, 1H), 6.88 (s, 1H), 7.12 (s, 1H), 7.63 (s, 1H), 9.69 (s, 1H),
11.65 (s, 1H). HRMS (ESIþ): found 291.13396 (Calcd. for
C15H19O4N2 [MþH]þ: 291.13393).
Methyl 4-methoxy-1H-indole-2-carboxylate (11e): white solid,
yield, 65%; m.p. 143-145 1C. 1H NMR (400 MHz, DMSO-d6): δ
3.86 (s, 3H), 3.88 (s, 3H), 6.53 (d, 1H, J¼7.6 Hz), 7.02 (d, 1H,
J¼7.6 Hz), 7.09 (s, 1H), 7.18 (t, 1H, J¼7.6 Hz), 11.92 (s, 1H).
13C NMR (126 MHz, DMSO-d6): δ 52.36, 55.34, 100.05, 105.36,
105.99, 118.37, 126.23, 126.33, 139.21, 154.28, 162.05. HRMS
(ESIþ): found 206.08092 (Calcd. for C11H12O3N [MþH]þ:
206.08117).
Methyl 4-(benzyloxy)-6-methoxy-1H-indole-2-carboxylate
(12e): white solid, yield, 85%. m.p. 182-183 1C. 1H NMR
(400 MHz, DMSO-d6): δ 3.74 (s, 3H), 3.81 (s, 3H), 5.20 (s,
2H), 6.28 (s, 1H), 6.46 (s, 1H), 7.03 (s, 1H), 7.32 (t, 1H,
J¼7.2 Hz), 7.39 (t, 2H, J¼7.2 Hz), 7.48 (d, 2H, J¼7.2 Hz),
11.69 (s, 1H). HRMS (ESIþ): found 312.12275 (Calcd. for
C18H18O4N [MþH]þ: 312.12303).
Methyl 4-(benzyloxy)-1H-indole-2-carboxylate (13e): white
solid, yield, 82%. m.p. 192-193 1C. 1H NMR (400 MHz,
DMSO-d6): δ 3.86 (s, 3H), 5.24 (s, 2H), 6.63 (d, 1H, J¼7.6 Hz),
7.03 (d, 1H, J¼7.6 Hz), 7.13 (s, 1H), 7.16 (t, 1H, J¼7.6 Hz), 7.36
(t, 1H, J¼7.6 Hz), 7.41 (t, 2H, J¼7.6 Hz), 7.52 (d, 2H, J¼7.6
Hz), 11.94 (s, 1H). HRMS (ESIþ): found 282.11227 (Calcd. for
C17H16O3N[MþH]þ: 282.11247).
Methyl 6-acetamido-1H-indole-2-carboxylate (14e): white
solid, yield, 70%; m.p. 235-237 1C. 1H NMR (400 MHz,
DMSO-d6): δ 2.05 (s, 3H), 3.83 (s, 3H), 7.07 (s, 1H), 7.10 (d,
1H, J¼8.8 Hz), 7.52 (d, 1H, J¼8.8 Hz), 8.01 (s, 1H), 9.95 (s,
1H), 11.75 (s, 1H). HRMS (ESIþ): found 233.09207 (Calcd. for
C12H13O3N2 [MþH]þ: 233.09188).
Methyl 6-(dimethylamino)-1H-indole-2-carboxylate (15e):
brown solid, yield, 67%; m.p. 177–178 1C. 1H NMR (400 MHz,
DMSO-d6): δ 2.91 (s, 6H), 3.80 (s, 3H), 6.56 (s, 1H), 6.74 (dd, 1H,
J¼8.8, 2.0 Hz), 6.99 (s, 1H), 7.43 (d, 1H, J¼8.8 Hz), 11.34 (s,
1H). 13C NMR (126 MHz, DMSO-d6): δ 41.22, 51.83, 93.62,
108.90, 111.03, 119.10, 122.57, 124.94, 139.97, 149.58, 161.97.
HRMS (ESIþ): found 219.11261 (Calcd. for C12H15O2N2
[MþH]þ: 219.11280).4.1.5. General procedure E for the preparation of compounds
1f–10f, 14f, 16f–18f
A solution of compounds 1e–3e, 5e–10e, 14e, 16e–18e (10 mmol)
in MeOH (50 mL) presaturated with hydrogen chloride was heated
under reﬂux for 2 h. After cooling, the solution was poured into
saturated sodium hydrogen carbonate (200 mL), and extracted
with ethyl acetate (3  80 mL). The combined organic layer was
dried over MgSO4. Filtered and concentrated, the residue was
recrystallized from anhydrous EtOH to afford the target
compounds.
Methyl 6-amino-4-methoxy-1H-indole-2-carboxylate (1f): pale
yellow solid, yield, 78%. m.p. 202-203 1C. 1H NMR (400 MHz,
DMSO-d6): δ 3.84 (s, 3H), 3.88 (s, 3H), 6.40 (s, 1H), 6.92 (s, 1H),
7.06 (s, 1H), 9.49 (br, 2H), 12.01 (s, 1H). HRMS (ESIþ ): found
221.09183 (Calcd. for C11H13O3N2 [MþH]þ: 221.09207).
Methyl 6-amino-4-(benzyloxy)-1H-indole-2-carboxylate (2f):
pale yellow solid, yield, 75%; m.p. 222-223 1C. 1H NMR
(400 MHz, DMSO-d6): δ 3.78 (s, 3H), 5.12 (s, 2H), 5.16 (s,
2H), 6.06 (s, 1H), 6.14 (s, 1H), 6.95 (s, 1H), 7.36 (t, 1H,
J¼7.6Hz),7.41 (t, 2H, J¼7.6 Hz), 7.49 (d, 2H, J¼7.6 Hz),
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C17H16O3N2 [M]
þ: 296.1161).
Methyl 6-amino-4-(4-ﬂuorobenzyloxy)-1H-indole-2-carboxy-
late (3f): pale yellow solid, yield, 70%; m.p. 254-256 1C. 1H
NMR (400 MHz, DMSO-d6): δ 3.84 (s, 3H), 5.21 (s, 2H), 6.49 (s,
1H), 6.94 (s, 1H), 7.12 (s, 1H), 7.24 (t, 2H, J¼8.4 Hz), 7.56 (dd,
2H, J¼5.6, 8.4 Hz), 9.54 (br, 2H), 12.04 (s, 1H). 13C NMR
(126 MHz, DMSO-d6): δ 52.15, 69.05, 97.38, 105.60, 115.72,
115.89, 127.13, 130.17, 130.23, 133.03, 138.45, 153.26, 153.57,
161.34, 161.74, 163.28. HRMS (ESIþ): found 315.11399 (Calcd.
for C17H16O3N2F [MþH]þ: 315.11395).
Methyl 6-amino-4-(4-methoxybenzyloxy)-1H-indole-2-carbox-
ylate (4f): pale yellow solid, yield, 61%; m.p. 270-272 1C. 1H
NMR (400 MHz, DMSO-d6): δ 3.83 (s, 3H), 3.89 (s, 3H),5.13 (s,
2H), 6.28 (s, 1H), 6.77 (s, 1H), 7.09 (s, 1H), 7.28 (t, 2H,
J¼8.0 Hz), 7.50 (dd, 2H, J¼5.2, 8.0 Hz), 9.61 (br, 2H), 11.99
(s, 1H). HRMS (ESIþ): found 327.13388 (Calcd. for C18H19O3N2
[MþH]þ: 327.13393).
Methyl 6-amino-4-(cyclohexylmethoxy)-1H-indole-2-carboxy-
late (5f): pale yellow solid, yield, 73%; m.p. 240-242 1C. 1H
NMR (400 MHz, CDCl3): δ 1.08-1.31 (m, 5H), 1.65-1.85 (m, 6H),
3.83 (s, 3H), 3.87 (d, 2H, J¼5.6 Hz), 6.34 (s, 1H), 6.82 (s, 1H),
7.06 (s, 1H), 9.18 (br, 2H), 11.92 (s, 1H). 13C NMR (126 MHz,
DMSO-d6): δ 25.78, 26.49, 29.52, 37.12, 52.36, 73.44, 85.82,
96.48, 105.59, 115.00, 116.73, 126.96, 138.44, 154.10, 161.77.
HRMS (ESIþ): found 303.17031 (Calcd. for C17H23O3N2
[MþH]þ: 303.17032).
Methyl 4-(allyloxy)-6-amino-1H-indole-2-carboxylate (6f): pale
yellow solid, yield, 65%; m.p. 230-231 1C. 1H NMR (400 MHz,
DMSO-d6): δ 3.85 (s, 3H), 4.68 (d, 2H, J¼5.2Hz), 5.30 (d, 1H,
J¼6.4 Hz), 5.48 (d, 1H, J¼17.2 Hz), 6.06-6.16 (m, 1H), 6.46 (s,
1H), 6.99 (s, 1H), 7.11 (s, 1H), 9.75 (br, 2H), 12.08 (s, 1H). 13C
NMR (126 MHz, DMSO-d6): δ 52.14, 69.05, 97.11, 100.16,
105.58, 117.14, 118.26, 127.25, 133.59, 138.45, 153.59, 161.69.
HRMS (ESIþ): found 247.10758 (Calcd. for C13H15O3N2
[MþH]þ: 247.10772).
Methyl 6-amino-4-cyclopropoxy-1H-indole-2-carboxylate (7f):
pale yellow solid, yield, 90%. m.p. 251-253 1C. 1H NMR
(400 MHz, DMSO-d6): δ 0.37-0.40 (m, 2H), 0.58-0.62 (m, 2H),
1.29-1.34 (m, 1H), 3.84 (s, 3H), 3.94 (d, 2H, J¼6.8 Hz), 6.38 (s,
1H), 6.91 (s, 1H), 7.07 (s, 1H), 9.50 (br, 2H), 12.00 (s, 1H).
HRMS (ESIþ): found 261.12305 (Calcd. for C14H17O3N2
[MþH]þ: 261.12337).
Methyl 6-amino-4-isobutoxy-1H-indole-2-carboxylate (8f): pale
yellow solid, yield, 68%; m.p. 230–233 1C. 1H NMR (400 MHz,
DMSO-d6): δ 1.02 (d, 6H, J¼6.8 Hz), 2.08-2.14 (m, 1H), 3.84 (d,
2H, J¼6.4 Hz), 3.85 (s, 3H), 6.42 (s, 1H), 6.95 (s, 1H), 7.10 (s,
1H), 9.62 (br, 2H), 12.04 (s, 1H). 13C NMR (126 MHz, DMSO-
d6): δ 19.30, 28.20, 52.36, 74.48, 96.49, 105.39, 126.69, 138.44,
149.09, 149.31, 153.90, 161.47. HRMS (ESIþ): found 263.13892
(Calcd. for C14H19O3N2 [MþH]þ: 263.13902).
Methyl 6-amino-4-ethoxy-1H-indole-2-carboxylate (9f): pale yel-
low solid, yield, 65%. m.p. 184-186 1C. 1H NMR (400 MHz, DMSO-
d6): δ 1.35 (s, 3H), 3.86 (s, 3H), 3.97 (s, 2H), 6.60 (s, 1H), 6.79 (s,
1H), 7.08 (s, 1H), 9.27 (br, 2H), 11.75 (s, 1H). HRMS (ESIþ): found
235.10768 (Calcd. for C12H15O3N2 [MþH]þ: 235.10772).
Methyl 6-amino-4-isopropoxy-1H-indole-2-carboxylate (10f):
pale yellow solid, yield, 70%. m.p. 171-173 1C. 1H NMR
(400 MHz, DMSO-d6): δ 1.37 (s, 6H), 3.86 (s, 3H), 4.10 (s,
1H), 6.67 (s, 1H), 6.84 (s, 1H), 7.00 (s, 1H), 9.47 (br, 2H), 11.88
(s, 1H). HRMS (ESIþ): found 249.12330 (Calcd. for C13H17O3N2
[MþH]þ: 249.12337).Methyl 6-amino-1H-indole-2-carboxylate (14f): pale yellow
solid, yield, 65%; m.p. 240-242 1C. 1H NMR (400 MHz,
DMSO-d6): δ 3.87 (s, 3H), 7.01 (s, 1H), 7.19 (s, 1H), 7.40 (s,
1H), 7.72 (d, 1H, J¼8.4 Hz), 9.79 (br, 2H), 12.01 (s, 1H). 13C
NMR (151 MHz, DMSO-d6): δ 52.27, 107.22, 107.87, 115.73,
123.32, 126.15, 128.63, 129.81, 137.43, 161.87. HRMS (ESIþ):
found 191.08137 (Calcd. for C10H11O2N2 [MþH]þ: 191.08150).
Methyl 7-amino-4-methoxy-1H-indole-2-carboxylate (16f): pale
yellow solid, yield, 70%. m.p. 184-185 1C. 1H NMR (500 MHz,
CDCl3): δ 3.89-3.99 (m, 8H), 6.32 (d, 1H, J¼8.0 Hz), 6.64 (d,
1H, J¼8.0 Hz), 7.47 (d, 1H, J¼8.0 Hz), 9.04 (s, 1H). HRMS
(ESIþ): found 221.09209 (Calcd. for C11H13O3N2 [MþH]þ:
221.09207).
Methyl 7-amino-4-ethoxy-1H-indole-2-carboxylate (17f): pale
yellow solid, yield, 75%. m.p. 138–140 1C. 1H NMR (500 MHz,
CDCl3): δ 1.44-1.47 (t, J¼7.0 Hz, 3H), 3.94 (s, 3H), 4.10 (q, 2H,
J¼7.0 Hz), 6.33 (d, 1H, J¼8 Hz), 6.59 (d, 1H, J¼8.0 Hz), 7.35
(s, 1H), 8.92 (s, 1H). HRMS (ESIþ): found 235.10787 (Calcd. for
C12H15O3N2 [MþH]þ: 235.10772).
Methyl 7-amino-4-propoxy-1H-indole-2-carboxylate (18f): pale
yellow solid, yield, 76%. m.p. 130–132 1C. 1H NMR (500 MHz,
CDCl3): δ 1.05–1.09 (t, 3H, J¼7.0 Hz), 1.82-1.89 (m, 2H), 3.95
(s, 3H), 3.98–4.01 (t, 2H, J¼6.5 Hz), 6.34 (d, 1H, J¼8.0 Hz),
6.59 (d, 1H, J¼7.5 Hz), 7.34 (s, 1H), 8.96 (s, 1H). HRMS (ESIþ):
found 249.12349 (Calcd. for C13H17O3N2 [MþH]þ: 249.12337).
4.2. Antiviral assays
Madin-Darby Canine Kidney (MDCK) cells and Coxsackie
viruses (Cox B3 Nancy strain) were purchased from ATCC.
Inﬂuenza A strains were all obtained from the Institute of
Virology, Chinese Academy of Preventive Medicine.
4.2.1. Anti-Coxsackie B3 activity assays
Conﬂuent Vero cells grown in 96-well plates were infected with a
median tissue culture infective dose of 100 (100TCID50) Cox B3
viruses. After 1 h of viral adsorption at 37 1C, the monolayers
were washed with phosphate buffered saline (PBS) and incubated
at 37 1C in the maintenance medium (MEMþ2% fetal bovine
serum (FBS)) with or without different concentrations of test
compounds. Viral cytopathic effect (CPE) was measured when the
viral control group reached a level of 4 and the antiviral activity of
test compounds was determined by the Reed and Muench
analyses.
4.2.2. Anti-inﬂuenza assays
Conﬂuent MDCK cells grown in 96-well microplates were
infected with inﬂuenza A at a median tissue culture infective dose
TCID50 of 100. After 2 h of viral adsorption at 37 1C, the
monolayers were washed with PBS and incubated at 37 1C in
the maintenance medium with or without different concentrations
of test compounds. Viral cytopathic effect (CPE) was measured
when the viral control group reached a value of 4 and the antiviral
activities of the synthesized compounds were determined by Reed
and Muench analyses.
4.2.3. Anti-HSV assays in vitro
Conﬂuent Vero cells grown in 96-well microplates were infected
with 100TCID50 HSV-1 virus respectively. HEL cells were
infected with HCMV. Tests were performed as follows: After
1hr adsorption at 37 1C, the monolayer cells were washed by PBS
Synthesis and antiviral activity of indole-2-carboxylate derivatives 321and incubated at 37 1C in the maintenance medium (MEMþ2%
FBS) with or without different concentrations of test compounds
or positive control drug. CPE was observed when viral control
group reached 4þ and the antiviral activity of compound was
determined by the Reed & Muench analyses.
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